National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Adult Acute Myeloid Leukemia Treatment (PDQ®)     
Last Modified: 09/08/2009
Health Professional Version
Changes to This Summary (09/08/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Classification 1

Added text 2 about the prognostic usefulness of gene-expression profiles (GEPs) in acute myeloid leukemia and specifically in predicting molecular subtypes; GEPs identified cases of core-binding factor leukemias that were not diagnosed using conventional cytogenetics (cited Valk et al. as reference 10, Haferlach et al. as reference 11, and Verhaak et al. as reference 12).

Added text 3 about a study that examined mutations and treatment outcomes in cytogenetically normal acute myeloid leukemia patients who were treated with intensive induction and postremission regimens (cited Schlenk et al. as reference 43 and level of evidence 3iiiA).

Stage Information 4

Added this new section.



Table of Links

1http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional/9.
cdr#Section_9
2http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional/33
8.cdr#Section_338
3http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional/33
9.cdr#Section_339
4http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional/33
0.cdr#Section_330